Page last updated: 2024-08-18

pyrroles and Angina, Unstable

pyrroles has been researched along with Angina, Unstable in 82 studies

Research

Studies (82)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (2.44)18.2507
2000's67 (81.71)29.6817
2010's13 (15.85)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Ballantyne, CM; Barter, PJ; Chapman, MJ; Erbel, R; Kataoka, Y; Libby, P; Nicholls, SJ; Nissen, SE; Puri, R; Raichlen, JS; Shao, M; Uno, K1
Bash, D; Brennan, DM; Cavender, MA; Jukema, JW; Kastelein, JJ; Koenig, W; Lincoff, AM; Menon, V; Nambi, V; Nicholls, SJ; Nissen, SE; Rosenson, RS; Schwartz, GG; Wright, RS1
Li, L; Liu, Y; Su, Q; Sun, Y; Wang, J; Zhou, Y1
Dicker, D; Elis, A; Gevrielov-Yusim, N; Goldenberg, I; Klempfner, R; Kopel, E; Matetzky, S; Pereg, D1
Berdan, LG; Bessac, L; Bhatt, DL; Bittner, V; Diaz, R; Goodman, SG; Hanotin, C; Harrington, RA; Jukema, JW; Mahaffey, KW; Moryusef, A; Pordy, R; Roe, MT; Rorick, T; Sasiela, WJ; Schwartz, GG; Shirodaria, C; Steg, PG; Szarek, M; Tamby, JF; Tricoci, P; White, H; Zeiher, A1
Bangalore, S; Breazna, A; DeMicco, DA; Messerli, FH; Wun, CC1
Briel, M; Bucher, HC; Nordmann, A; Schwartz, G; Vale, N1
Ge, ZM; Geng, J; Kang, WQ; Wang, W; Zhang, Y; Zhao, Z1
Cater, NB; Faergeman, O; Fayyad, R; Holme, I; Kastelein, JJ; Larsen, ML; Lindahl, C; Olsson, AG; Pedersen, TR; Szarek, M; Tikkanen, MJ1
Braunwald, E; Cannon, CP; McCabe, CH; Murphy, SA; Wiviott, SD1
Bonassin, F; Schneemann, M; Wyss, C1
Chen, WQ; Ge, ZM; Geng, J; Ji, XP; Ren, SD; Wu, TT; Yu, XL; Zhang, HJ; Zhong, L1
Armani, A; Cannon, CP; McCabe, CH; Murphy, SA; Truong, QA1
Akçalı, Z; Borlu, F; Namal, E; Oztekin, E; Sener, N; Ulaş, T1
Daida, H; Hasegawa, Y; Hirayama, A; Hiro, T; Kadota, K; Kimura, K; Kimura, T; Matsuzaki, M; Miyauchi, K; Morimoto, T; Nakagawa, Y; Ozaki, Y; Uchiyama, S; Yamagishi, M1
Gong, P; Lin, J; Liu, S; Lu, J; Lu, X; Qiu, J; Wang, H; Zhang, X1
Chaitman, BR; Ezekowitz, M; Ganz, P; Leslie, SJ; Oliver, MF; Olsson, AG; Schwartz, GG; Stern, T; Waters, DD; Zeiher, A1
Ammirati, F; Colivicchi, F; Guido, V; Montefoschi, N; Santini, M; Tubaro, M; Varveri, A1
Nissen, SE1
Correia, LC; D'Oliveira, A; Esteves, JP; Magalhães, LP; Passos, LC; Rocha, MS; Santana, O; Spósito, AC1
Böhm, M; Fries, R1
Correia, LC; D'Oliveira, A; Esteves, JP; Lima, JC; Magalhães, LP; Passos, LC; Rocha, MS; Spósito, AC1
Ganz, P; Kinlay, S; Leslie, SJ; Libby, P; Olsson, AG; Rifai, N; Sasiela, WJ; Schwartz, GG; Szarek, M1
Arikian, S; Ganz, P; Schwartz, GG; Waters, D1
Arsenault, M; Auclair, L; Bogaty, P; Boyer, L; Dagenais, GR; Jobin, J; Pépin, G; Poirier, P1
Cannon, CP1
Belder, R; Braunwald, E; Cannon, CP; Hill, KA; Joyal, SV; McCabe, CH; Pfeffer, MA; Rader, DJ; Rouleau, JL; Skene, AM1
Topol, EJ1
Li, J; Xu, Z; Ye, H; Zhao, S; Zhou, H1
Aukrust, P; Damås, JK; Frøland, SS; Gullestad, L; Haug, T; Semb, AG; Smith, C; Tunheim, SH; Waehre, T; Yndestad, A1
Chalikias, GK; Chatseras, DI; Hatzinikolaou, EI; Karas, SM; Papadopoulos, ED; Papadopoulou, EG; Parissis, JT; Tentes, IK; Tripsiannis, GA; Tziakas, DN1
Daida, H; Miyauchi, K; Shimada, K1
Casciano, R; Olsson, A; Stern, L; Svangren, P1
Ganz, P; Kinlay, S; Libby, P; Olsson, AG; Rifai, N; Sasiela, WJ; Schwartz, GG; Szarek, M1
LeLorier, J; Paradis, JM1
Gotto, AM1
Miller, M2
Auer, J; Eber, B; Weber, T1
Cao, LS; Feng, YB; Li, DZ; Ranjit, S; Tian, Y; Wang, X; Zeng, QT1
Miller, ER; Olsson, AG; Sasiela, WJ; Schwartz, GG; Szarek, M; Tsimikas, S; Witztum, JL1
Lange, AP; Szucs, TD1
von Schacky, C1
Bartuś, S; Chyrchel, M; Dubiel, JS; Dudek, D; Heba, G; Legutko, J1
Casciano, R; Gómez-Gerique, JA; Rejas, J; Stern, L1
Farmer, JA1
Ezekowitz, MD; Ganz, P; Oliver, MF; Olsson, AG; Sasiela, WJ; Schwartz, GG; Szarek, M; Waters, D; Zeiher, A1
Antoniades, C; Bosinakou, E; Katsi, V; Kotsopoulou, M; Stefanadis, C; Tousoulis, D; Tsioufis, C1
Fang, CH; Li, JJ1
Liu, HX; Luo, Y; Xie, XM1
Aukrust, P; Boullier, A; Damås, JK; Green, S; Quehenberger, O; Sandberg, WJ; Smith, C; Waehre, T1
Braunwald, E; Cairns, R; Cannon, CP; Jackson, G; McCabe, CH; Ray, KK; Sacks, FM; Tonkin, AM1
Braunwald, E; Cannon, CP; Morrow, DA; Pfeffer, MA; Ray, KK; Wiviott, SD1
Braunwald, E; Cairns, R; Cannon, CP; Gibson, CM; Kirtane, AJ; McCabe, CH; Morrow, DA; Ray, KK; Ridker, PM; Rifai, N; Skene, AM1
Fonarow, GC1
Antoniades, C; Bosinakou, E; Katsi, V; Kotsopoulou, M; Stefanadis, C; Tousoulis, D1
Blazing, M; Braunwald, E; Califf, R; Cannon, CP; de Lemos, JA; McCabe, CH; Murphy, SA; Wiviott, SD1
Braunwald, E; Cairns, R; Cannon, CP; Mega, JL; Morrow, DA; Murphy, S; Ridker, PM1
Asai, K; Ito, T; Kosaka, T; Kuhara, Y; Kuroda, Y; Ozaki, Y; Shinjo, H; Takashima, H; Wakita, Y; Waseda, K; Yasukawa, T1
Braunwald, E; Giugliano, RP1
Chen, YH; Chua, S; Hang, CL; Hung, WC; Wu, CJ; Yeh, KH; Yip, HK; Youssef, AA1
Alberti, A; Bergamasco, L; Brscic, E; Celeste, A; De Bernardi, A; Formato, L; Fuster, V; Moretti, C; Pucci, A; Sheiban, I; Trevi, G1
Betteridge, DJ; Colhoun, HM; DeMicco, DA; Durrington, PN; Fuller, JH; Hitman, GA; Livingstone, SJ; Luo, D; Neil, HA1
Kurbanov, RD; Shek, AB; Tashkenbaeva, NF1
Colonna, G; Di Sciascio, G; Fischetti, D; Miglionico, M; Montinaro, A; Pasceri, V; Patti, G; Sardella, G1
Abad, L; Chaves, J; Dueñas, A; Hernandez, G; Pérez-Castrillón, JL; Sanz, A; Vega, G1
Botteman, MF; Damen, J; Koren, MJ; Kuntze, CE; Liu, LZ; Mamdani, M; Straka, RJ1
Blazing, MA; Braunwald, E; Califf, RM; Cannon, CP; de Lemos, JA; McCabe, CH; Murphy, SA; Wiviott, SD1
Kazantseva, MO; Logacheva, IV1
Bacarea, A; Dobreanu, D; Dobreanu, M; Fodor, A1
Loscalzo, J; Pitt, B; Raichlen, JS; Ycas, J1
Black, D; Chaitman, BR; Ezekowitz, MD; Ganz, P; Kane, JP; Oliver, MF; Olsson, AG; Pressler, ML; Schwartz, GG; Texter, M; Waters, D1
Ghali, JK1
Mitka, M1
Puel, J1
Chaitman, BR; Ezekowitz, MD; Ganz, P; Leslie, S; Oliver, MF; Olsson, AG; Schwartz, GG; Stern, T; Waters, D; Zeiher, A1
Sacks, FM1
Breen, WJ; Johnson, K1
Hsue, PY; Waters, DD1
Ahsan, CH; Ezekowitz, M; Shah, A1
Belder, R; Braunwald, E; Breen, J; Cannon, CP; McCabe, CH1
Braga, JC; Correia, LC; D'Oliveira, A; Esteves, JP; Lima, JC; Passos, LC; Rocha, MS; Spósito, AC1

Reviews

7 review(s) available for pyrroles and Angina, Unstable

ArticleYear
Pathobiology, not angiography, should guide management in acute coronary syndrome/non-ST-segment elevation myocardial infarction: the non-interventionist's perspective.
    Journal of the American College of Cardiology, 2003, Feb-19, Volume: 41, Issue:4 Suppl S

    Topics: Acute Disease; Angina, Unstable; Angioplasty, Balloon, Coronary; Atorvastatin; Coronary Angiography; Coronary Artery Disease; Disease Progression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Outcome Assessment, Health Care; Pyrroles; Randomized Controlled Trials as Topic

2003
[Update cardiology 2001/2002-part II. From unstable coronary syndrome to terminal heart failure].
    Medizinische Klinik (Munich, Germany : 1983), 2003, Jun-15, Volume: 98, Issue:6

    Topics: Abciximab; Acute Disease; Adrenergic beta-Antagonists; Angina, Unstable; Antibodies, Monoclonal; Anticholesteremic Agents; Arrhythmias, Cardiac; Aspirin; Atorvastatin; Clopidogrel; Defibrillators, Implantable; Double-Blind Method; Fibrinolytic Agents; Heart Failure; Heart Septal Defects, Atrial; Heart Transplantation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunoglobulin Fab Fragments; Myocardial Infarction; Placebos; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrroles; Quality of Life; Randomized Controlled Trials as Topic; Regeneration; Risk Factors; Syndrome; Ticlopidine; Time Factors; Tirofiban; Tyrosine

2003
The next step in cardiovascular protection.
    Atherosclerosis. Supplements, 2003, Volume: 4, Issue:5

    Topics: Angina, Unstable; Anti-Bacterial Agents; Anticholesteremic Agents; Atorvastatin; Chlamydia Infections; Chlamydophila pneumoniae; Cholesterol, LDL; Clinical Trials as Topic; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pravastatin; Pyrroles; Secondary Prevention

2003
In-hospital initiation of statin therapy in acute coronary syndromes: maximizing the early and long-term benefits.
    Chest, 2005, Volume: 128, Issue:5

    Topics: Angina, Unstable; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Myocardial Ischemia; Pravastatin; Pyrroles; Syndrome; Treatment Outcome

2005
The year in non-ST-segment elevation acute coronary syndromes.
    Journal of the American College of Cardiology, 2006, Jul-18, Volume: 48, Issue:2

    Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Atorvastatin; Biomarkers; Clopidogrel; Coronary Vessels; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Multivariate Analysis; Myocardial Infarction; Platelet Aggregation Inhibitors; Pravastatin; Prognosis; Pyrroles; Risk Assessment; Stents; Syndrome; Thrombolytic Therapy; Ticlopidine

2006
[Statins and unstable angina: MIRACL].
    Annales d'endocrinologie, 2001, Volume: 62, Issue:1 Pt 2

    Topics: Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Cholesterol; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Ischemia; Pyrroles

2001
What is the role of intensive cholesterol lowering in the treatment of acute coronary syndromes?
    The American journal of cardiology, 2001, Oct-11, Volume: 88, Issue:7B

    Topics: Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Cholesterol; Clinical Trials as Topic; Coronary Artery Disease; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Myocardial Infarction; Pyrroles; Treatment Outcome

2001

Trials

44 trial(s) available for pyrroles and Angina, Unstable

ArticleYear
Coronary atheroma volume and cardiovascular events during maximally intensive statin therapy.
    European heart journal, 2013, Volume: 34, Issue:41

    Topics: Angina, Unstable; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Female; Fluorobenzenes; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Plaque, Atherosclerotic; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Stroke; Sulfonamides; Treatment Outcome; Ultrasonography, Interventional

2013
Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial.
    JAMA, 2014, Jan-15, Volume: 311, Issue:3

    Topics: Acetates; Acute Coronary Syndrome; Aged; Angina, Unstable; Atherosclerosis; Atorvastatin; Double-Blind Method; Early Termination of Clinical Trials; Female; Heptanoic Acids; Humans; Indoles; Keto Acids; Male; Middle Aged; Myocardial Infarction; Phospholipases A; Phospholipases A2, Secretory; Pyrroles; Risk; Stroke; Survival Analysis; Treatment Outcome

2014
Effect of intensive atorvastatin therapy on periprocedural PDCD4 expression in CD4+ T lymphocytes of patients with unstable angina undergoing percutaneous coronary intervention.
    Cardiology, 2014, Volume: 127, Issue:3

    Topics: Aged; Angina, Unstable; Apoptosis Regulatory Proteins; Atorvastatin; C-Reactive Protein; CD4-Positive T-Lymphocytes; Creatine Kinase, MB Form; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-10; Male; Percutaneous Coronary Intervention; Pyrroles; RNA-Binding Proteins; RNA, Messenger; Troponin I; Tumor Necrosis Factor-alpha

2014
Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial.
    American heart journal, 2014, Volume: 168, Issue:5

    Topics: Acute Coronary Syndrome; Angina, Unstable; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Fluorobenzenes; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Myocardial Infarction; Proprotein Convertase 9; Proprotein Convertases; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Serine Endopeptidases; Stroke; Sulfonamides; Treatment Outcome

2014
Visit-to-visit low-density lipoprotein cholesterol variability and risk of cardiovascular outcomes: insights from the TNT trial.
    Journal of the American College of Cardiology, 2015, Apr-21, Volume: 65, Issue:15

    Topics: Adult; Aged; Angina, Unstable; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Follow-Up Studies; Heart Arrest; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Pyrroles; Stroke

2015
Efficacy and safety of atorvastatin during early hospitalization in elderly patients with unstable angina.
    Clinical and experimental pharmacology & physiology, 2009, Volume: 36, Issue:5-6

    Topics: Aged; Aged, 80 and over; Angina, Unstable; Anti-Inflammatory Agents; Anticholesteremic Agents; Atorvastatin; Dose-Response Relationship, Drug; Endothelium, Vascular; Female; Heptanoic Acids; Hospitalization; Humans; Inflammation Mediators; Length of Stay; Lipids; Male; Middle Aged; Pyrroles; Treatment Outcome

2009
Total cardiovascular disease burden: comparing intensive with moderate statin therapy insights from the IDEAL (Incremental Decrease in End Points Through Aggressive Lipid Lowering) trial.
    Journal of the American College of Cardiology, 2009, Dec-15, Volume: 54, Issue:25

    Topics: Angina, Unstable; Atorvastatin; Coronary Disease; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Myocardial Infarction; Myocardial Revascularization; Proportional Hazards Models; Pyrroles

2009
Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection T
    Journal of the American College of Cardiology, 2009, Dec-15, Volume: 54, Issue:25

    Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Atorvastatin; C-Reactive Protein; Cholesterol; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Myocardial Infarction; Myocardial Revascularization; Pravastatin; Pyrroles; Regression Analysis; Secondary Prevention; Stroke

2009
Effects of loading dose of atorvastatin before percutaneous coronary intervention on periprocedural myocardial injury.
    Coronary artery disease, 2011, Volume: 22, Issue:1

    Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Atorvastatin; Biomarkers; C-Reactive Protein; Chi-Square Distribution; China; Creatine Kinase, MB Form; Double-Blind Method; Drug Administration Schedule; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Prospective Studies; Pyrroles; Risk Assessment; Risk Factors; Secondary Prevention; Time Factors; Treatment Outcome; Troponin I

2011
Benefit of intensive statin therapy in women: results from PROVE IT-TIMI 22.
    Circulation. Cardiovascular quality and outcomes, 2011, Volume: 4, Issue:3

    Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Atorvastatin; Biomarkers; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Male; Middle Aged; Myocardial Infarction; Pravastatin; Pyrroles; Sex Characteristics; Stroke; Treatment Outcome

2011
[Effects of different statins, ezetimibe/simvastatin combination on hsCRP levels in unstable angina pectoris and non-ST elevation myocardial infarction patients: a randomized trial].
    Anadolu kardiyoloji dergisi : AKD = the Anatolian journal of cardiology, 2011, Volume: 11, Issue:8

    Topics: Angina, Unstable; Atorvastatin; Azetidines; C-Reactive Protein; Drug Combinations; Ezetimibe, Simvastatin Drug Combination; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Single-Blind Method; Sulfonamides; Treatment Outcome

2011
Intensive-dose atorvastatin regimen halts progression of atherosclerotic plaques in new-onset unstable angina with borderline vulnerable plaque lesions.
    Journal of cardiovascular pharmacology and therapeutics, 2013, Volume: 18, Issue:2

    Topics: Aged; Angina, Unstable; Atorvastatin; Disease Progression; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Plaque, Atherosclerotic; Prospective Studies; Pyrroles

2013
Effects of atorvastatin on stroke in patients with unstable angina or non-Q-wave myocardial infarction: a Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) substudy.
    Circulation, 2002, Sep-24, Volume: 106, Issue:13

    Topics: Acute Disease; Aged; Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Cholesterol; Electrocardiography; Female; Follow-Up Studies; Heptanoic Acids; Humans; Incidence; Lipids; Male; Myocardial Infarction; Myocardial Ischemia; Proportional Hazards Models; Pyrroles; Risk; Risk Assessment; Secondary Prevention; Stroke; Treatment Outcome

2002
Effects of atorvastatin 80 mg daily early after onset of unstable angina pectoris or non-Q-wave myocardial infarction.
    The American journal of cardiology, 2002, Oct-15, Volume: 90, Issue:8

    Topics: Aged; Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Cardiovascular Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Myocardial Infarction; Pyrroles; Recurrence; Survival Rate

2002
Effect of atorvastatin (80 mg) on recurrent ischemia in unstable angina pectoris or non-ST-elevation acute myocardial infarction.
    The American journal of cardiology, 2003, Jun-01, Volume: 91, Issue:11

    Topics: Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography, Ambulatory; Female; Heptanoic Acids; Humans; Logistic Models; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Pyrroles; Recurrence; Treatment Outcome

2003
Anti-inflammatory effect of atorvastatin (80 mg) in unstable angina pectoris and non-Q-wave acute myocardial infarction.
    The American journal of cardiology, 2003, Aug-01, Volume: 92, Issue:3

    Topics: Aged; Angina, Unstable; Anti-Inflammatory Agents; Anticholesteremic Agents; Atorvastatin; Biomarkers; C-Reactive Protein; Cholesterol; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Pyrroles; Syndrome; Treatment Outcome

2003
High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study.
    Circulation, 2003, Sep-30, Volume: 108, Issue:13

    Topics: Acute Disease; Aged; Angina, Unstable; Apolipoproteins; Atorvastatin; Biomarkers; C-Reactive Protein; Cholesterol, LDL; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Interleukin-6; Male; Middle Aged; Myocardial Infarction; Pyrroles; Serum Amyloid A Protein; Syndrome; Troponin

2003
Effect of atorvastatin on exercise-induced myocardial ischemia in patients with stable angina pectoris.
    The American journal of cardiology, 2003, Nov-15, Volume: 92, Issue:10

    Topics: Aged; Angina, Unstable; Atorvastatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Exercise Test; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Myocardial Ischemia; Pyrroles

2003
Intensive versus moderate lipid lowering with statins after acute coronary syndromes.
    The New England journal of medicine, 2004, Apr-08, Volume: 350, Issue:15

    Topics: Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Pravastatin; Proportional Hazards Models; Pyrroles

2004
Atorvastatin lowers plasma matrix metalloproteinase-9 in patients with acute coronary syndrome.
    Clinical chemistry, 2004, Volume: 50, Issue:4

    Topics: Acute Disease; Angina, Unstable; Atorvastatin; Coronary Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Matrix Metalloproteinase 9; Middle Aged; Myocardial Infarction; Pyrroles

2004
Increased expression of interleukin-1 in coronary artery disease with downregulatory effects of HMG-CoA reductase inhibitors.
    Circulation, 2004, Apr-27, Volume: 109, Issue:16

    Topics: Angina Pectoris; Angina, Unstable; Atorvastatin; Coronary Artery Disease; Cross-Sectional Studies; Down-Regulation; Female; Gene Expression Profiling; Gene Expression Regulation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-1; Leukocytes, Mononuclear; Male; Middle Aged; Oligonucleotide Array Sequence Analysis; Pyrroles; Simvastatin; Tumor Necrosis Factor-alpha

2004
Serum profiles of matrix metalloproteinases and their tissue inhibitor in patients with acute coronary syndromes. The effects of short-term atorvastatin administration.
    International journal of cardiology, 2004, Volume: 94, Issue:2-3

    Topics: Aged; Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Cytokines; Female; Heptanoic Acids; Humans; Male; Matrix Metalloproteinases; Middle Aged; Myocardial Infarction; Pyrroles; Tissue Inhibitor of Metalloproteinases

2004
Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study.
    Circulation, 2004, Jul-27, Volume: 110, Issue:4

    Topics: Aged; Angina Pectoris; Angina, Unstable; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Biomarkers; CD40 Ligand; Double-Blind Method; Female; Heart Arrest; Heptanoic Acids; Humans; Inflammation Mediators; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Pyrroles; Recurrence; Risk; Solubility; Treatment Outcome

2004
High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial.
    Circulation, 2004, Sep-14, Volume: 110, Issue:11

    Topics: Aged; Angina, Unstable; Antigen-Antibody Complex; Apolipoprotein B-100; Apolipoproteins B; Atorvastatin; Autoantibodies; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunoglobulin G; Immunoglobulin M; Lipoprotein(a); Lipoproteins, LDL; Male; Middle Aged; Myocardial Infarction; Oxidation-Reduction; Phospholipids; Pyrroles

2004
High-dose statin and COX-2 inhibitor therapy rapidly decreases C-reactive protein level in patients with unstable angina.
    Kardiologia polska, 2004, Volume: 61, Issue:9

    Topics: Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Atorvastatin; C-Reactive Protein; Coronary Angiography; Cyclooxygenase Inhibitors; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lactones; Male; Middle Aged; Pyrroles; Sulfones; Treatment Outcome

2004
High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from the MIRACL trial.
    European heart journal, 2005, Volume: 26, Issue:9

    Topics: Aged; Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Double-Blind Method; Female; Heptanoic Acids; Humans; Lipoproteins, HDL; Male; Myocardial Infarction; Myocardial Ischemia; Prognosis; Proportional Hazards Models; Pyrroles; Recurrence

2005
The impact of early administration of low-dose atorvastatin treatment on inflammatory process, in patients with unstable angina and low cholesterol level.
    International journal of cardiology, 2006, Apr-28, Volume: 109, Issue:1

    Topics: Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Chemokine CCL2; Cholesterol; Female; Heptanoic Acids; Humans; Inflammation; Interleukin-6; Male; Middle Aged; Prospective Studies; Pyrroles; Time Factors; Tumor Necrosis Factor-alpha; Vascular Cell Adhesion Molecule-1

2006
Effects of 4 weeks of atorvastatin administration on the antiinflammatory cytokine interleukin-10 in patients with unstable angina.
    Clinical chemistry, 2005, Volume: 51, Issue:9

    Topics: Angina, Unstable; Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-10; Pyrroles

2005
[Effect of atorvastatin on the nuclear factor-kappaB and soluble inter-cellular adhesion molecules-1 in patients with acute coronary syndrome].
    Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences, 2004, Volume: 29, Issue:1

    Topics: Aged; Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Female; Heptanoic Acids; Humans; Intercellular Adhesion Molecule-1; Male; Middle Aged; Myocardial Infarction; NF-kappa B; Pyrroles

2004
Expression of fractalkine (CX3CL1) and its receptor, CX3CR1, is elevated in coronary artery disease and is reduced during statin therapy.
    Arteriosclerosis, thrombosis, and vascular biology, 2005, Volume: 25, Issue:12

    Topics: Angina, Unstable; Atorvastatin; Cell Adhesion; Cells, Cultured; Chemokine CX3CL1; Chemokines, CX3C; Chemotaxis; Cholesterol, LDL; Coronary Artery Disease; CX3C Chemokine Receptor 1; Endothelium, Vascular; Gene Expression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-8; Leukocytes, Mononuclear; Membrane Proteins; Myocardial Infarction; Pyrroles; Receptors, Chemokine; Simvastatin; Umbilical Veins

2005
Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial.
    Journal of the American College of Cardiology, 2005, Oct-18, Volume: 46, Issue:8

    Topics: Acute Disease; Angina, Unstable; Atorvastatin; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Pravastatin; Pyrroles; Syndrome; Time Factors

2005
Relationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 trial.
    Journal of the American College of Cardiology, 2005, Oct-18, Volume: 46, Issue:8

    Topics: Acute Disease; Aged; Angina, Unstable; Atorvastatin; C-Reactive Protein; Cross-Sectional Studies; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Pravastatin; Pyrroles; Risk Factors; Syndrome

2005
Effects of early administration of atorvastatin treatment on thrombotic process in normocholesterolemic patients with unstable angina.
    International journal of cardiology, 2006, Jan-26, Volume: 106, Issue:3

    Topics: Angina, Unstable; Atorvastatin; Biomarkers; Blood Coagulation; Blood Coagulation Factors; Blood Proteins; Cholesterol; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Prospective Studies; Pyrroles

2006
Cholesterol, C-reactive protein, and cerebrovascular events following intensive and moderate statin therapy.
    Journal of thrombosis and thrombolysis, 2006, Volume: 22, Issue:1

    Topics: Aged; Angina, Unstable; Atorvastatin; C-Reactive Protein; Cholesterol; Epidemiologic Methods; Female; Fluoroquinolones; Gatifloxacin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Pravastatin; Pyrroles; Stroke

2006
In vivo coronary plaque histology in patients with stable and acute coronary syndromes: relationships with hyperlipidemic status and statin treatment.
    Atherosclerosis, 2007, Volume: 194, Issue:1

    Topics: Acute Disease; Aged; Angina, Unstable; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Atherectomy, Coronary; Atorvastatin; Coronary Artery Disease; Coronary Vessels; Female; Glycophorins; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Immunohistochemistry; Male; Middle Aged; Pravastatin; Pyrroles

2007
Analysis of efficacy and safety in patients aged 65-75 years at randomization: Collaborative Atorvastatin Diabetes Study (CARDS).
    Diabetes care, 2006, Volume: 29, Issue:11

    Topics: Adult; Age Distribution; Aged; Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Coronary Disease; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Male; Middle Aged; Myocardial Infarction; Pyrroles; Risk Factors; Risk Reduction Behavior; Stroke

2006
[Effects of atorvastatin and acipimox on the lipid spectrum of blood plasma, endothelial function and a clinical course of unstable angina pectoris].
    Terapevticheskii arkhiv, 2006, Volume: 78, Issue:8

    Topics: Angina, Unstable; Atorvastatin; Brachial Artery; Cholesterol, LDL; Drug Therapy, Combination; Endothelium, Vascular; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Pyrazines; Pyrroles; Treatment Outcome; Vasodilation

2006
Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial.
    Journal of the American College of Cardiology, 2007, Mar-27, Volume: 49, Issue:12

    Topics: Acute Disease; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Atorvastatin; Coronary Disease; Double-Blind Method; Female; Heptanoic Acids; Humans; Male; Middle Aged; Myocardial Infarction; Prospective Studies; Pyrroles; Syndrome; Time Factors; Treatment Outcome

2007
Effect of intensive lipid-lowering therapy on mortality after acute coronary syndrome (a patient-level analysis of the Aggrastat to Zocor and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 trials).
    The American journal of cardiology, 2007, Oct-01, Volume: 100, Issue:7

    Topics: Aged; Angina, Unstable; Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Pravastatin; Pyrroles; Simvastatin; Tirofiban; Treatment Outcome; Tyrosine

2007
[Immunoinflammatory factors in unstable angina. Possibility of influence of atorvastatin].
    Kardiologiia, 2007, Volume: 47, Issue:6

    Topics: Angina, Unstable; Atorvastatin; C-Reactive Protein; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunity, Cellular; Inflammation; Interleukin-4; Male; Middle Aged; Pyrroles; T-Lymphocytes; Treatment Outcome; Tumor Necrosis Factor-alpha

2007
Rationale and design of the Myocardial Ischemia Reduction With Aggressive Cholesterol lowering (MIRACL) Study that evaluates atorvastatin in unstable angina pectoris and in non-Q-wave acute myocardial infarction.
    The American journal of cardiology, 1998, Sep-01, Volume: 82, Issue:5

    Topics: Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Cholesterol; Coronary Disease; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hypercholesterolemia; Myocardial Infarction; Pyrroles; Research Design

1998
Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial.
    JAMA, 2001, Apr-04, Volume: 285, Issue:13

    Topics: Aged; Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Myocardial Infarction; Proportional Hazards Models; Pyrroles; Recurrence; Survival Analysis

2001
Acute statin treatment in reducing risk after acute coronary syndrome: the MIRACL (Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering) Trial.
    Current opinion in cardiology, 2001, Volume: 16, Issue:6

    Topics: Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Double-Blind Method; Health Behavior; Heart Conduction System; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Primary Prevention; Prospective Studies; Pyrroles; Treatment Outcome

2001
Short-term effect of atorvastatin (80 mg) on plasma lipids of patients with unstable angina pectoris or non-Q-wave acute myocardial infarction.
    The American journal of cardiology, 2002, Jul-15, Volume: 90, Issue:2

    Topics: Aged; Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Cholesterol; Female; Heptanoic Acids; Humans; Lipids; Male; Middle Aged; Myocardial Infarction; Pyrroles; Treatment Outcome; Triglycerides

2002

Other Studies

31 other study(ies) available for pyrroles and Angina, Unstable

ArticleYear
Temporal trends in the use of high-dose potent statins following acute coronary syndrome in Israel.
    Cardiology, 2014, Volume: 128, Issue:3

    Topics: Analysis of Variance; Angina, Unstable; Atorvastatin; Cohort Studies; Drug Prescriptions; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Israel; Male; Medication Adherence; Middle Aged; Myocardial Infarction; Patient Discharge; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome

2014
Cochrane corner: early statin therapy in acute coronary syndromes--what is the clinical benefit?
    Heart (British Cardiac Society), 2016, Volume: 102, Issue:9

    Topics: Angina, Unstable; Anticholesteremic Agents; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Myocardial Infarction; Pyrroles

2016
[Managing myocardial infarct in general practice].
    Praxis, 2010, Jul-07, Volume: 99, Issue:14

    Topics: Acute Coronary Syndrome; Algorithms; Angina, Unstable; Anticoagulants; Atorvastatin; Blood Chemical Analysis; Chest Pain; Clopidogrel; Coronary Angiography; Drug Therapy, Combination; Education, Medical, Continuing; Electroencephalography; Family Practice; Heparin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Prognosis; Pyrroles; Risk Factors; Switzerland; Ticlopidine

2010
Reverse vessel remodeling but not coronary plaque regression could predict future cardiovascular events in ACS patients with intensive statin therapy--the extended JAPAN-ACS study.
    Circulation journal : official journal of the Japanese Circulation Society, 2012, Volume: 76, Issue:4

    Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Atorvastatin; Biomarkers; Cerebral Infarction; Cholesterol, HDL; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Plaque, Atherosclerotic; Predictive Value of Tests; Proportional Hazards Models; Pyrroles; Quinolines; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Ultrasonography, Interventional

2012
Pharmacoeconomic evaluation of the effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes.
    The American journal of cardiology, 2003, Nov-01, Volume: 92, Issue:9

    Topics: Acute Disease; Angina, Unstable; Atorvastatin; Cost-Benefit Analysis; Economics, Pharmaceutical; Health Care Costs; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Myocardial Ischemia; Pyrroles; Secondary Prevention; Syndrome

2003
Intensive statin therapy--a sea change in cardiovascular prevention.
    The New England journal of medicine, 2004, Apr-08, Volume: 350, Issue:15

    Topics: Angina, Unstable; Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pravastatin; Pyrroles

2004
Early intervention with atorvastatin modulates TH1/TH2 imbalance in patients with acute coronary syndrome: from bedside to bench.
    Circulation, 2004, May-11, Volume: 109, Issue:18

    Topics: Acute Disease; Angina Pectoris; Angina, Unstable; Anion Exchange Resins; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Atorvastatin; CD4 Lymphocyte Count; Coronary Disease; Epichlorohydrin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Imidazoles; Immunophenotyping; Male; Prospective Studies; Pyrroles; Resins, Synthetic; Th1 Cells; Th2 Cells

2004
A pharmacoeconomic evaluation of aggressive cholesterol lowering in Sweden.
    International journal of cardiology, 2004, Volume: 96, Issue:1

    Topics: Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Cost-Benefit Analysis; Health Care Costs; Heptanoic Acids; Humans; Myocardial Infarction; Pyrroles; Retrospective Studies; Sweden; Syndrome; Time Factors; Treatment Outcome

2004
Intensive versus moderate lipid lowering with statins after acute coronary syndromes.
    The New England journal of medicine, 2004, Aug-12, Volume: 351, Issue:7

    Topics: Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Patient Dropouts; Pravastatin; Pyrroles

2004
Intensive versus moderate lipid lowering with statins after acute coronary syndromes.
    The New England journal of medicine, 2004, Aug-12, Volume: 351, Issue:7

    Topics: Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pravastatin; Pyrroles

2004
Intensive versus moderate lipid lowering with statins after acute coronary syndromes.
    The New England journal of medicine, 2004, Aug-12, Volume: 351, Issue:7

    Topics: Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pravastatin; Pyrroles; Triglycerides

2004
Intensive versus moderate lipid lowering with statins after acute coronary syndromes.
    The New England journal of medicine, 2004, Aug-12, Volume: 351, Issue:7

    Topics: Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pravastatin; Pyrroles

2004
[Effects of atorvastatin on the function of dendritic cells in patients with unstable angina pectoris].
    Zhonghua nei ke za zhi, 2004, Volume: 43, Issue:6

    Topics: Adult; Aged; Angina, Unstable; Antigens, CD; Atorvastatin; B7-2 Antigen; Cells, Cultured; Cytokines; Dendritic Cells; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lymphocyte Culture Test, Mixed; Male; Membrane Glycoproteins; Middle Aged; Pyrroles

2004
[Cost-effectiveness of atorvastatin in the early treatment of acute coronary syndromes in Germany based on the MIRACL study].
    Medizinische Klinik (Munich, Germany : 1983), 2004, Sep-15, Volume: 99, Issue:9

    Topics: Acute Disease; Adolescent; Adult; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Atorvastatin; Cost Savings; Cost-Benefit Analysis; Costs and Cost Analysis; Diagnosis-Related Groups; Double-Blind Method; Germany; Heptanoic Acids; Humans; Middle Aged; Myocardial Infarction; Patient Compliance; Placebos; Pyrroles; Randomized Controlled Trials as Topic; Retrospective Studies; Syndrome; Time Factors

2004
[Statin therapy in patients with acute coronary syndrome. "Prove-it" study].
    Der Internist, 2004, Volume: 45, Issue:12

    Topics: Angina, Unstable; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Pravastatin; Proportional Hazards Models; Pyrroles; Randomized Controlled Trials as Topic; Syndrome; Treatment Outcome

2004
A pharmacoeconomic evaluation of the effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes in Spain.
    The European journal of health economics : HEPAC : health economics in prevention and care, 2004, Volume: 5, Issue:3

    Topics: Acute Disease; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Atorvastatin; Coronary Artery Bypass; Cost Savings; Cost-Benefit Analysis; Diagnosis-Related Groups; Double-Blind Method; Economics, Pharmaceutical; Heptanoic Acids; Humans; Multicenter Studies as Topic; Myocardial Infarction; Placebos; Pyrroles; Randomized Controlled Trials as Topic; Recurrence; Risk Factors; Spain; Syndrome; Time Factors; Treatment Outcome

2004
Intensive versus moderate lipid lowering with statins in acute coronary syndromes.
    Current atherosclerosis reports, 2005, Volume: 7, Issue:2

    Topics: Adolescent; Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hyperlipidemias; Multicenter Studies as Topic; Myocardial Infarction; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors; Survival Rate; Treatment Outcome

2005
Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy.
    Journal of the American College of Cardiology, 2005, Oct-18, Volume: 46, Issue:8

    Topics: Acute Disease; Angina, Unstable; Atorvastatin; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Male; Middle Aged; Myocardial Infarction; Pravastatin; Pyrroles; Syndrome

2005
A tale of two trials: a comparison of the post-acute coronary syndrome lipid-lowering trials A to Z and PROVE IT-TIMI 22.
    Circulation, 2006, Mar-21, Volume: 113, Issue:11

    Topics: Aged; Angina, Unstable; Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Case Management; Chemical and Drug Induced Liver Injury; Comorbidity; Confounding Factors, Epidemiologic; Dose-Response Relationship, Drug; Endpoint Determination; Female; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Tables; Lipids; Male; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Myocardial Ischemia; Myocardial Revascularization; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Research Design; Risk; Risk Factors; Simvastatin; Stroke; Tirofiban; Treatment Outcome; Tyrosine

2006
[Regression of a large lipid-rich pool in the coronary artery during treatment with statin detected by intravascular ultrasound: a case report].
    Journal of cardiology, 2006, Volume: 47, Issue:6

    Topics: Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Coronary Angiography; Coronary Disease; Coronary Vessels; Heptanoic Acids; Humans; Hypercholesterolemia; Lipids; Male; Middle Aged; Pyrroles; Stents; Ultrasonography, Interventional

2006
Re-elevation of high-sensitivity C-reactive protein but not the von Willebrand Factor after withdrawing atorvastatin therapy in patients with unstable angina undergoing coronary artery stenting.
    International heart journal, 2006, Volume: 47, Issue:4

    Topics: Angina, Unstable; Atorvastatin; Biomarkers; C-Reactive Protein; Coronary Angiography; Coronary Artery Bypass; Disease Progression; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunoenzyme Techniques; Male; Middle Aged; Nephelometry and Turbidimetry; Prognosis; Pyrroles; Retrospective Studies; Severity of Illness Index; Stents; Time Factors; von Willebrand Factor

2006
Effects of Atorvastatin on vitamin D levels in patients with acute ischemic heart disease.
    The American journal of cardiology, 2007, Apr-01, Volume: 99, Issue:7

    Topics: Aged; Angina, Unstable; Atorvastatin; Calcifediol; Case-Control Studies; Cholesterol, HDL; Cholesterol, LDL; Chromatography, High Pressure Liquid; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Metabolic Networks and Pathways; Middle Aged; Myocardial Infarction; Pyrroles; Treatment Outcome; Triglycerides; Vitamin D; Vitamin D Deficiency

2007
Economic impacts attributable to the early clinical benefit of atorvastatin therapy--a US managed care perspective.
    Current medical research and opinion, 2007, Volume: 23, Issue:7

    Topics: Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Coronary Disease; Costs and Cost Analysis; Diabetes Mellitus; Drug Costs; Female; Heptanoic Acids; Humans; Male; Models, Theoretical; Pyrroles; Simvastatin; United States

2007
Integrin expression on monocytes and lymphocytes in unstable angina short term effects of atorvastatin.
    Romanian journal of internal medicine = Revue roumaine de medecine interne, 2007, Volume: 45, Issue:2

    Topics: Adult; Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Case-Control Studies; Cohort Studies; Coronary Artery Disease; Female; Flow Cytometry; Heptanoic Acids; Humans; Hypercholesterolemia; Integrin alpha Chains; Lymphocyte Activation; Male; Middle Aged; Monocytes; Pyrroles; T-Lymphocytes

2007
Lipid levels in the post-acute coronary syndrome setting: destabilizing another myth?
    Journal of the American College of Cardiology, 2008, Apr-15, Volume: 51, Issue:15

    Topics: Acute Coronary Syndrome; Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Fluorobenzenes; Heptanoic Acids; Humans; Prognosis; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Time Factors

2008
Lipid levels after acute coronary syndromes.
    Journal of the American College of Cardiology, 2008, Apr-15, Volume: 51, Issue:15

    Topics: Acute Coronary Syndrome; Adolescent; Adult; Aged; Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Female; Fluorobenzenes; Heart Conduction System; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Prognosis; Prospective Studies; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Sulfonamides; Time Factors; Triglycerides

2008
Rationale and design of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study that evaluates atorvastatin in unstable angina pectoris and in non-Q-wave acute myocardial infarction.
    The American journal of cardiology, 1998, Mar-01, Volume: 81, Issue:5

    Topics: Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Heptanoic Acids; Humans; Multicenter Studies as Topic; Myocardial Infarction; Myocardial Ischemia; Pyrroles; Randomized Controlled Trials as Topic; Recurrence; Research Design; Treatment Outcome

1998
Fast, aggressive treatment for myocardial infarction urged.
    JAMA, 2000, Dec-20, Volume: 284, Issue:23

    Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Atorvastatin; Coronary Artery Bypass; Heptanoic Acids; Humans; Hypolipidemic Agents; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrroles; Stents; Tirofiban; Tyrosine

2000
Lipid-lowering therapy in acute coronary syndromes.
    JAMA, 2001, Apr-04, Volume: 285, Issue:13

    Topics: Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Myocardial Infarction; Pyrroles

2001
Can early treatment with atorvastatin (Lipitor) improve the outcome of patients with acute coronary syndromes?
    The Journal of family practice, 2001, Volume: 50, Issue:7

    Topics: Adult; Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Controlled Clinical Trials as Topic; Double-Blind Method; Heptanoic Acids; Humans; Myocardial Infarction; Pyrroles; Time Factors

2001
Design of the Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT)-TIMI 22 trial.
    The American journal of cardiology, 2002, Apr-01, Volume: 89, Issue:7

    Topics: Angina, Unstable; Anti-Infective Agents; Anticholesteremic Agents; Atorvastatin; Chlamydophila Infections; Chlamydophila pneumoniae; Cholesterol, LDL; Double-Blind Method; Fluoroquinolones; Gatifloxacin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Multicenter Studies as Topic; Myocardial Infarction; Pneumonia, Bacterial; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Research Design

2002